Advances in Anti-VEGF Therapy Exploring the Impact of Aflibercept 8mg
Available from: 23/12/2024 (AEDT)
Where to publish: www.mieducation.com
Provider: Mivision
Contact: Nikki Byrne, [E] nikki@mivision.com.au, [P] 02 8336 8616
Learning Objectives
- Be aware of the evolution of treatments for nAMD and DMO
- Realise the mechanism of action of anti-VEGF therapy
- Be aware of challenges associated with early anti-VEGF therapies
- Be aware of new anti-VEGF therapies and early trial results
Max CPD hours awarded: 1.25
Session Information
| Name |
|---|
| Advances in Anti-VEGF Therapy Exploring the Impact of Aflibercept 8mg |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 0.75 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1.25 |